A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD8154 Following Single Ascending Dose Administration in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 02 Jan 2019
At a glance
- Drugs AZD-8154 (Primary)
- Indications Asthma
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
- 21 Dec 2019 Planned End Date changed from 16 Jan 2019 to 30 Apr 2019.
- 21 Dec 2019 Planned primary completion date changed from 16 Jan 2019 to 30 Apr 2019.
- 31 Aug 2018 Biomarkers information updated